Financial Data and Key Metrics Changes - The company reported organic sales growth of 7.5% excluding COVID test sales, with earnings per share rising to $1.30, reflecting high single-digit growth compared to last year [5][13] - Adjusted gross margin was 55.8% of sales, showing a decrease from the prior year due to tariffs, while adjusted operating margin increased by 40 basis points to 23% [14][48] Business Line Data and Key Metrics Changes - Nutrition sales increased by 4%, driven by a 10% growth in international markets, particularly in adult nutrition products like Ensure and Glucerna [6][7] - Diagnostics experienced modest sales growth excluding COVID testing, with core lab diagnostics growing 7% outside of China, while point-of-care diagnostics grew by 8% [7][8] - Established Pharmaceuticals (EPD) sales increased by 7%, led by double-digit growth in key markets, with strong contributions from therapeutic areas like gastroenterology and cardiometabolic [8][9] - Medical devices saw a 12.5% sales growth, with significant contributions from diabetes care and electrophysiology [9][10] Market Data and Key Metrics Changes - The U.S. diagnostics market grew by 10%, while the European region saw growth of 6% to 7%, and Latin America grew in the mid-teens [44] - In China, the company faced challenges due to VBP pricing dynamics, but growth in other segments like EPD and nutrition remained strong, with an overall growth rate of around 5% to 7% when excluding diagnostics [61][62] Company Strategy and Development Direction - The company aims to sustain high single-digit organic sales growth and double-digit EPS growth, supported by new product launches and a strong existing portfolio [21][22] - Investments in innovation and clinical trials are expected to drive future growth, with nearly 200 clinical trials planned across various businesses [21][23] - The company is focused on expanding its market share in key areas such as diabetes care and electrophysiology, with new product launches like Volt expected to enhance growth [19][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting consensus estimates for 2026, citing underlying momentum in the current portfolio and easing headwinds from diagnostics [18][19] - The company anticipates a recovery in the diagnostics business as it laps previous headwinds, with expectations for mid-to-high single-digit growth next year [45] - Management highlighted the importance of adapting to market conditions and maintaining a resilient portfolio to drive growth [19][23] Other Important Information - The company has launched new products that generated nearly half a billion dollars in sales this quarter, contributing significantly to organic sales growth [6] - Regulatory approvals for new medical devices, such as Triclip in Japan and expanded indications for TAVR, are expected to enhance market position [10][11] Q&A Session Summary Question: Thoughts on 2026 sales and EPS consensus - Management is comfortable with the consensus estimates for 2026, expecting to deliver similar growth rates as in 2025 despite headwinds faced this year [18] Question: Insights on U.S. diabetes market growth - U.S. diabetes care grew by 19%, with expectations for continued strong growth driven by new product launches and increased penetration in the basal segment [26][28] Question: Drivers of ablation catheter growth - Double-digit growth in ablation catheters is driven significantly by international markets, with a strong competitive position in mapping cases [52][53] Question: Outlook for diagnostics business in China - Management expects mid-single-digit growth in China, focusing on expanding contributions from other geographies while navigating current challenges [62] Question: Update on nutrition litigation and market performance - The company remains committed to defending its products amid ongoing litigation, with pockets of softness in nutrition being addressed through strategic investments [80]

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Abbott reported quarterly earnings of $1.3 per share, matching the Zacks Consensus Estimate, and showing an increase from $1.21 per share a year ago [1] - The company posted revenues of $11.37 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.24%, but up from $10.64 billion year-over-year [2] - Abbott's shares have increased by approximately 17.8% year-to-date, outperforming the S&P 500's gain of 13% [3] Earnings Performance - Over the last four quarters, Abbott has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is $1.49, with expected revenues of $11.75 billion, and for the current fiscal year, the estimate is $5.15 on revenues of $44.66 billion [7] Market Outlook - The sustainability of Abbott's stock price movement will largely depend on management's commentary during the earnings call [3] - The Zacks Rank for Abbott is currently 4 (Sell), indicating expectations of underperformance in the near future [6] - The Medical - Products industry, to which Abbott belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

THIRD-QUARTER 2025 RESULTS $5.4B MEDICAL DEVICES $1.5B ESTABLISHED $2.2B NUTRITION $5.12 to $5.183 REAFFIRMED FULL-YEAR GUIDANCE TOTAL COMPANY SALES $11.4B +7.5%1 Organic* sales growth for underlying base business** ADJUSTED DILUTED EPS $1.302 KEY BUSINESS UNITS ADJUSTED DILUTED EPS Narrowed range reflects double-digit growth at the midpoint 7.5% to 8.0%3 ORGANIC SALES GROWTH Excluding COVID-19 testing-related sales BUSINESS HIGHLIGHTS EXPANDING ALTERNATIVES TO OPEN-HEART SURGERY EXTENDING GLOBAL REACH OF S ...

Core Insights - Abbott Laboratories reported adjusted earnings of $1.30 per share on $11.37 billion in third-quarter sales, slightly missing sales expectations of $11.39 billion [1][2] - The company reaffirmed its sales guidance for 7.5% to 8% organic sales growth for the year, excluding the impact of Covid tests, and narrowed its earnings outlook to a range of $5.12 to $5.18 per share [2] Financial Performance - In the same quarter last year, Abbott earned $1.21 per share on $10.64 billion in sales, indicating a year-over-year earnings increase of approximately 7.4% and sales growth of about 6.9% [2] - Analysts projected an average earnings per share of $5.15 and total sales of $44.69 billion for the year [2] Stock Market Reaction - In premarket trading, Abbott's stock fell nearly 3% to $128.94, breaking out of a cup-with-handle base with a buy point at $134.71 [3] - The stock is currently below the 5% chase zone and facing resistance at its 50-day moving average [3]

The company narrowed its guidance for the second time this year. ...

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults ...

Core Insights - Abbott reported higher quarterly revenue, attributed to strong demand for its medical devices, particularly continuous glucose monitors and heart devices [1] Group 1: Financial Performance - The increase in revenue was driven by robust sales in the medical devices segment [1] Group 2: Product Demand - Continuous glucose monitors and heart devices were highlighted as key contributors to the revenue growth [1]

[News Release & Highlights](index=1&type=section&id=News%20Release) [CEO Statement](index=1&type=section&id=CEO%20Statement) Robert B. Ford, Chairman and CEO, highlighted consistent, high-quality performance in Q3 2025, attributing it to a differentiated product pipeline that positions Abbott for durable long-term value to shareholders - Robert B. Ford, chairman and chief executive officer, Abbott, stated: 'Our third-quarter results demonstrate our ability to deliver **consistent, high-quality performance**. Our differentiated product pipeline continues to power our performance and positions Abbott to deliver **durable long-term value** to our shareholders'[2](index=2&type=chunk) [Key Financial Highlights (3Q25 & YTD)](index=1&type=section&id=Key%20Financial%20Highlights) Abbott reported strong financial results for Q3 2025, with significant sales growth and adjusted diluted EPS, alongside positive year-to-date performance, demonstrating consistent execution Key Financial Highlights (3Q25 & YTD) | Metric | 3Q25 Reported | 3Q25 Organic (excl. COVID-19) | YTD Reported | YTD Organic (excl. COVID-19) | | :----- | :------------ | :---------------------------- | :----------- | :--------------------------- | | Sales Growth | 6.9% | 7.5% | 6.1% | 7.7% | | GAAP Diluted EPS | $0.94 | N/A | N/A | N/A | | Adjusted Diluted EPS | $1.30 | N/A | N/A | N/A | | Reported Operating Margin | 18.1% | N/A | N/A | N/A | | Adjusted Operating Margin | 23.0% (40 bps increase) | N/A | N/A | N/A | [Recent Product & Regulatory Milestones](index=1&type=section&id=Recent%20Product%20%26%20Regulatory%20Milestones) Abbott achieved key regulatory approvals and received supportive treatment guidelines for its innovative medical devices, enhancing its market position in cardiovascular health - Regulatory approval in Japan for TriClip®, a first-of-its-kind, minimally invasive treatment option for patients with tricuspid regurgitation[2](index=2&type=chunk) - CE Mark received for an expanded indication for the Navitor® transcatheter aortic valve implantation (TAVI) system to treat symptomatic, severe aortic stenosis patients at low or intermediate risk for open-heart surgery[2](index=2&type=chunk) - New treatment guidelines issued at the European Society of Cardiology (ESC) Congress provide additional support for the use of MitraClip® and TriClip® in treating valvular heart disease[2](index=2&type=chunk) [Third-Quarter Business Overview](index=2&type=section&id=THIRD-QUARTER%20BUSINESS%20OVERVIEW) [Overall Sales Performance (3Q25 & 9M25)](index=2&type=section&id=Overall%20Sales%20Performance) Abbott's overall sales demonstrated solid growth in Q3 and year-to-date 2025, particularly when excluding the declining impact of COVID-19 testing sales, with organic growth being a key metric for performance assessment - Management measures sales growth rates on an organic basis, excluding foreign exchange impact and the discontinuation of the ZonePerfect® product line, to understand core underlying business performance[3](index=3&type=chunk) Total Company Sales (3Q25 vs 3Q24) | Metric | Total Company | Nutrition | Diagnostics | Established Pharmaceuticals | Medical Devices | | :----- | :------------ | :-------- | :---------- | :------------------------ | :-------------- | | Total reported sales ($M) | 11,369 | 2,153 | 2,253 | 1,511 | 5,448 | | Total reported % Change | 6.9% | 4.2% | (6.6)% | 7.5% | 14.8% | | Organic % Change | 5.5% | 4.0% | (7.8)% | 7.1% | 12.5% | | Organic (excl. COVID-19 tests) % Change | 7.5% | 4.0% | 0.4% | 7.1% | 12.5% | Total Company Sales (9M25 vs 9M24) | Metric | Total Company | Nutrition | Diagnostics | Established Pharmaceuticals | Medical Devices | | :----- | :------------ | :-------- | :---------- | :------------------------ | :-------------- | | Total reported sales ($M) | 32,869 | 6,511 | 6,480 | 4,154 | 15,712 | | Total reported % Change | 6.1% | 3.6% | (5.0)% | 5.8% | 12.8% | | Organic % Change | 6.4% | 4.7% | (4.8)% | 7.5% | 12.4% | | Organic (excl. COVID-19 tests) % Change | 7.7% | 4.7% | 0.6% | 7.5% | 12.4% | [Nutrition Segment Performance](index=3&type=section&id=Nutrition) The Nutrition segment achieved reported sales growth of 4.2% and organic growth of 4.0% in Q3 2025, primarily driven by strong performance in Adult Nutrition, particularly from Ensure® and Glucerna® brands Nutrition Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Pediatric | Adult | | :------------------------ | :---- | :-------- | :---- | | U.S. | 888 | 520 | 368 | | International | 1,265 | 457 | 808 | | Total reported | 2,153 | 977 | 1,176 | | % Change vs. 3Q24 | | | | | U.S. | (6.5) | (8.4) | (3.8) | | International | 13.3 | 17.9 | 10.9 | | Total reported | 4.2 | 2.3 | 5.8 | | Impact of foreign exchange | 0.2 | (0.1) | 0.4 | | Organic | 4.0 | 2.4 | 5.4 | - Growth in the quarter was led by Adult Nutrition, with sales increasing **5.8 percent reported** and **5.4 percent organic**, driven by strong growth of Ensure® and Glucerna®[9](index=9&type=chunk) Nutrition Sales (9M25 vs 9M24) | Sales 9M25 ($ in millions) | Total | Pediatric | Adult | | :------------------------ | :---- | :-------- | :---- | | U.S. | 2,800 | 1,695 | 1,105 | | International | 3,711 | 1,377 | 2,334 | | Total reported | 6,511 | 3,072 | 3,439 | | % Change vs. 9M24 | | | | | U.S. | 1.4 | 3.0 | (0.9) | | International | 5.3 | — | 8.8 | | Total reported | 3.6 | 1.6 | 5.5 | | Impact of foreign exchange | (0.9) | (0.9) | (0.9) | | Impact of business exit* | (0.2) | — | (0.4) | | Organic | 4.7 | 2.5 | 6.8 | [Diagnostics Segment Performance](index=4&type=section&id=Diagnostics) Global Diagnostics sales decreased in Q3 2025 on a reported and organic basis, primarily due to a significant decline in COVID-19 testing-related sales. Excluding COVID-19 tests, organic sales showed slight growth, with Core Laboratory Diagnostics experiencing growth despite challenging market conditions in China Diagnostics Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Core Laboratory | Molecular | Point of Care | Rapid Diagnostics | | :------------------------ | :---- | :-------------- | :-------- | :------------ | :---------------- | | U.S. | 886 | 366 | 36 | 111 | 373 | | International | 1,367 | 998 | 95 | 47 | 227 | | Total reported | 2,253 | 1,364 | 131 | 158 | 600 | | % Change vs. 3Q24 | | | | | | | U.S. | (14.1) | 10.4 | (1.5) | 7.9 | (33.5) | | International | (1.0) | 1.6 | 4.3 | 8.9 | (14.2) | | Total reported | (6.6) | 3.8 | 2.6 | 8.2 | (27.3) | | Impact of foreign exchange | 1.2 | 1.6 | 1.8 | 0.4 | 0.4 | | Organic | (7.8) | 2.2 | 0.8 | 7.8 | (27.7) | | Organic (excluding COVID-19 tests) | 0.4 | N/A | N/A | N/A | N/A | - COVID-19 testing-related sales were **$69 million** in Q3 2025, a significant decrease from **$265 million** in Q3 2024[10](index=10&type=chunk) - Core Laboratory Diagnostics sales increased **3.8 percent reported** and **2.2 percent organic**, despite challenging market conditions in China, including volume-based procurement programs[11](index=11&type=chunk) [Established Pharmaceuticals Segment Performance](index=5&type=section&id=Established%20Pharmaceuticals) Established Pharmaceuticals sales increased 7.5% on a reported basis and 7.1% organically in Q3 2025, primarily driven by double-digit organic growth in Key Emerging Markets across Asia, Latin America, and the Middle East Established Pharmaceuticals Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Key Emerging Markets | Other | | :------------------------ | :---- | :------------------- | :---- | | International | 1,511 | 1,097 | 414 | | Total reported | 1,511 | 1,097 | 414 | | % Change vs. 3Q24 | | | | | International | 7.5 | 10.3 | 0.6 | | Total reported | 7.5 | 10.3 | 0.6 | | Impact of foreign exchange | 0.4 | (0.8) | 3.1 | | Organic | 7.1 | 11.1 | (2.5) | - Sales in Key Emerging Markets increased **10.3 percent reported** and **11.1 percent organic**, driven by double-digit growth in several countries across Asia, Latin America, and the Middle East[14](index=14&type=chunk) Established Pharmaceuticals Sales (9M25 vs 9M24) | Sales 9M25 ($ in millions) | Total | Key Emerging Markets | Other | | :------------------------ | :---- | :------------------- | :---- | | International | 4,154 | 3,121 | 1,033 | | Total reported | 4,154 | 3,121 | 1,033 | | % Change vs. 9M24 | | | | | International | 5.8 | 7.3 | 1.7 | | Total reported | 5.8 | 7.3 | 1.7 | | Impact of foreign exchange | (1.7) | (2.4) | 0.5 | | Organic | 7.5 | 9.7 | 1.2 | [Medical Devices Segment Performance](index=6&type=section&id=Medical%20Devices) The Medical Devices segment delivered strong performance in Q3 2025, with reported sales increasing 14.8% and organic sales growing 12.5%, driven by double-digit growth across several key areas including Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, and Structural Heart Medical Devices Sales (3Q25 vs 3Q24) | Sales 3Q25 ($ in millions) | Total | Rhythm Management | Electrophysiology | Heart Failure | Vascular | Structural Heart | Neuromodulation | Diabetes Care | | :------------------------ | :---- | :---------------- | :---------------- | :------------ | :------- | :--------------- | :-------------- | :------------ | | U.S. | 2,521 | 350 | 322 | 280 | 280 | 297 | 196 | 796 | | International | 2,927 | 336 | 383 | 86 | 465 | 338 | 58 | 1,261 | | Total reported | 5,448 | 686 | 705 | 366 | 745 | 635 | 254 | 2,057 | | % Change vs. 3Q24 | | | | | | | | | | U.S. | 13.8 | 21.1 | 13.2 | 10.7 | 8.5 | 10.1 | 3.3 | 18.4 | | International | 15.6 | 9.3 | 17.6 | 22.6 | 5.5 | 16.9 | 24.9 | 19.9 | | Total reported | 14.8 | 15.0 | 15.6 | 13.3 | 6.6 | 13.6 | 7.6 | 19.3 | | Impact of foreign exchange | 2.3 | 2.0 | 1.9 | 1.2 | 1.9 | 2.3 | 0.8 | 3.1 | | Organic | 12.5 | 13.0 | 13.7 | 12.1 | 4.7 | 11.3 | 6.8 | 16.2 | - Sales growth in Q3 was led by **double-digit growth** in Diabetes Care, Electrophysiology, Rhythm Management, Heart Failure, and Structural Heart[17](index=17&type=chunk) - Diabetes Care sales of continuous glucose monitors reached **$2.0 billion**, growing **20.5 percent reported** and **17.2 percent organic**[17](index=17&type=chunk) [Abbott's Financial Guidance & Shareholder Information](index=7&type=section&id=ABBOTT%27S%20FINANCIAL%20GUIDANCE) [Full-Year 2025 Financial Guidance](index=7&type=section&id=Full-Year%202025%20Financial%20Guidance) Abbott reaffirmed its full-year 2025 organic sales growth guidance and narrowed its adjusted diluted EPS guidance range, reflecting anticipated double-digit growth - Abbott reaffirms full-year 2025 organic sales growth guidance of **7.5% to 8.0%** (excluding COVID-19 testing-related sales) or **6.0% to 7.0%** (including COVID-19 testing-related sales)[19](index=19&type=chunk) - Abbott reaffirms the midpoint of full-year 2025 adjusted diluted EPS guidance and narrows the range to **$5.12 to $5.18**, reflecting **double-digit growth** at the midpoint[19](index=19&type=chunk) [Dividend Declaration](index=7&type=section&id=ABBOTT%20DECLARES%20407%20CONSECUTIVE%20QUARTERLY%20DIVIDEND) Abbott declared its 407th consecutive quarterly dividend of $0.59 per share, payable in November 2025, underscoring its long-standing commitment to shareholder returns as a Dividend Aristocrat - On Sept. 19, 2025, Abbott's board of directors declared a quarterly dividend of **$0.59 per share**[21](index=21&type=chunk) - The cash dividend is payable Nov. 17, 2025, to shareholders of record on Oct. 15, 2025[21](index=21&type=chunk) - Abbott has increased its dividend payout for **53 consecutive years** and is a member of the S&P 500 Dividend Aristocrats Index[21](index=21&type=chunk) [Company Overview](index=7&type=section&id=About%20Abbott%3A) Abbott is a global healthcare leader providing life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with 114,000 employees - Abbott is a global healthcare leader with a portfolio of life-changing technologies spanning diagnostics, medical devices, nutritionals, and branded generic medicines[22](index=22&type=chunk) - The company has **114,000 colleagues** serving people in more than **160 countries**[22](index=22&type=chunk) [Financial Statements & Non-GAAP Reconciliations](index=9&type=section&id=Abbott%20Laboratories%20and%20Subsidiaries) [Condensed Consolidated Statement of Earnings](index=9&type=section&id=Condensed%20Consolidated%20Statement%20of%20Earnings) The condensed consolidated statements of earnings for Q3 and 9M 2025 show net sales growth and changes in operating earnings, net earnings, and diluted EPS compared to the prior year, both on a GAAP and adjusted basis Condensed Consolidated Statement of Earnings (3Q25 vs 3Q24) | Metric | 3Q25 ($M) | 3Q24 ($M) | % Change | | :----- | :-------- | :-------- | :------- | | Net Sales | $11,369 | $10,635 | 6.9% | | Operating Earnings | $2,057 | $1,859 | 10.6% | | Net Earnings (GAAP) | $1,644 | $1,646 | (0.1)% | | Net Earnings (excl. Specified Items) | $2,278 | $2,119 | 7.5% | | Diluted EPS (GAAP) | $0.94 | $0.94 | — | | Diluted EPS (excl. Specified Items) | $1.30 | $1.21 | 7.4% | Condensed Consolidated Statement of Earnings (9M25 vs 9M24) | Metric | 9M25 ($M) | 9M24 ($M) | % Change | | :----- | :-------- | :-------- | :------- | | Net Sales | $32,869 | $30,976 | 6.1% | | Operating Earnings | $5,802 | $4,914 | 18.1% | | Net Earnings (GAAP) | $4,748 | $4,173 | 13.8% | | Net Earnings (excl. Specified Items) | $6,410 | $5,851 | 9.6% | | Diluted EPS (GAAP) | $2.70 | $2.38 | 13.4% | | Diluted EPS (excl. Specified Items) | $3.65 | $3.33 | 9.6% | [Non-GAAP Financial Information Reconciliation](index=13&type=section&id=Non-GAAP%20Reconciliation%20of%20Financial%20Information) Abbott provides detailed reconciliations from GAAP to adjusted financial measures for Q3 and 9M 2025 and 2024, primarily adjusting for intangible amortization, restructuring, acquisition-related expenses, and other specified items to present a clearer view of core operational performance Non-GAAP Reconciliation (3Q25) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $420 | $(420) | $0 | | Gross Margin | $5,874 | $470 | $6,344 | | R&D | $766 | $(36) | $730 | | SG&A | $3,051 | $(47) | $3,004 | | Other (income) expense, net | $(150) | $5 | $(145) | | Earnings before taxes | $2,180 | $548 | $2,728 | | Taxes on Earnings | $536 | $(86) | $450 | | Net Earnings | $1,644 | $634 | $2,278 | | Diluted Earnings per Share | $0.94 | $0.36 | $1.30 | Non-GAAP Reconciliation (3Q24) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $470 | $(470) | $0 | | Gross Margin | $5,467 | $516 | $5,983 | | R&D | $713 | $(19) | $694 | | SG&A | $2,895 | $(5) | $2,890 | | Other (income) expense, net | $(121) | $(12) | $(133) | | Earnings before taxes | $1,940 | $552 | $2,492 | | Taxes on Earnings | $294 | $79 | $373 | | Net Earnings | $1,646 | $473 | $2,119 | | Diluted Earnings per Share | $0.94 | $0.27 | $1.21 | Non-GAAP Reconciliation (9M25) | Metric | As Reported (GAAP) ($M) | Specified Items ($M) | As Adjusted ($M) | | :----- | :---------------------- | :------------------- | :--------------- | | Intangible Amortization | $1,260 | $(1,260) | $0 | | Gross Margin | $17,212 | $1,396 | $18,608 | | R&D | $2,207 | $(83) | $2,124 | | SG&A | $9,203 | $(58) | $9,145 | | Other (income) expense, net | $(414) | $(31) | $(445) | | Earnings before taxes | $6,108 | $1,568 | $7,676 | | Taxes on Earnings | $1,360 | $(94) | $1,266 | | Net Earnings | $4,748 | $1,662 | $6,410 | | Diluted Earnings per Share | $2.70 | $0.95 | $3.65 | [Tax Rate Reconciliation](index=15&type=section&id=Tax%20Rate%20Reconciliation) Abbott reconciled its GAAP tax rates to adjusted tax rates for Q3 and 9M 2025 and 2024, showing the impact of specified items and certain tax adjustments on the effective tax rate Tax Rate Reconciliation (3Q25 vs 3Q24) | Metric | 3Q25 GAAP Tax Rate | 3Q25 Adjusted Tax Rate | 3Q24 GAAP Tax Rate | 3Q24 Adjusted Tax Rate | | :----- | :----------------- | :--------------------- | :----------------- | :--------------------- | | Tax Rate | 24.6% | 16.5% | 15.2% | 15.0% | Tax Rate Reconciliation (9M25 vs 9M24) | Metric | 9M25 GAAP Tax Rate | 9M25 Adjusted Tax Rate | 9M24 GAAP Tax Rate | 9M24 Adjusted Tax Rate | | :----- | :----------------- | :--------------------- | :----------------- | :--------------------- | | Tax Rate | 22.3% | 16.5% | 16.3% | 15.0% | [Non-GAAP Revenue Reconciliation](index=16&type=section&id=Non-GAAP%20Revenue%20Reconciliation) Abbott provided a non-GAAP revenue reconciliation for the nine months ended September 30, 2025 and 2024, detailing the impact of discontinuing the ZonePerfect® product line in the Nutrition business on reported and adjusted revenue figures Non-GAAP Revenue Reconciliation (9M25 vs 9M24) | Metric | 9M25 Abbott Reported ($M) | 9M24 Abbott Reported ($M) | Impact from business exit (a) ($M) | 9M24 Adjusted Revenue ($M) | % Change vs. 9M24 Reported | % Change vs. 9M24 Adjusted | Organic % Change | | :----- | :------------------------ | :------------------------ | :--------------------------------- | :------------------------- | :------------------------- | :------------------------- | :--------------- | | Total Company | 32,869 | 30,976 | (13) | 30,963 | 6.1% | 6.1% | 6.4% | | Total Nutrition | 6,511 | 6,284 | (13) | 6,271 | 3.6% | 3.8% | 4.7% | | Adult Nutrition | 3,439 | 3,261 | (13) | 3,248 | 5.5% | 5.9% | 6.8% | - The business exit impact reflects the discontinuation of the ZonePerfect® product line in the Nutrition business, initiated in March 2024[47](index=47&type=chunk) [Details of Specified Items](index=17&type=section&id=Details%20of%20Specified%20Items) This section provides a detailed breakdown of the specific items that are excluded from GAAP financial measures to arrive at adjusted (non-GAAP) figures for the third quarter and nine months ended September 30, 2025 and 2024. These items primarily include intangible amortization, restructuring and cost reduction initiatives, acquisition/divestiture-related expenses, and other adjustments - For 3Q25, specified items include **$420 million** for intangible amortization and **$128 million** for restructuring, acquisition costs, and other net expenses[38](index=38&type=chunk)[49](index=49&type=chunk) - For 3Q24, specified items include **$470 million** for intangible amortization and **$82 million** for intangible impairment, acquisitions, a divestiture, and other net expenses[39](index=39&type=chunk)[52](index=52&type=chunk) - For 9M25, specified items include **$1.260 billion** for intangible amortization and **$308 million** for restructuring, acquisitions, investment impairment charges, and other net expenses[42](index=42&type=chunk)[55](index=55&type=chunk) - For 9M24, specified items include **$1.413 billion** for intangible amortization and **$487 million** for restructuring, acquisitions, a divestiture, and other net expenses[43](index=43&type=chunk)[58](index=58&type=chunk)

Core Insights - Abbott's third-quarter results for 2025 show a total worldwide sales increase of 6.9% to $11.369 billion compared to $10.635 billion in the same quarter of 2024 [23] - The company reported a GAAP diluted EPS of $0.94 and an adjusted diluted EPS of $1.30, reflecting a 7.4% increase from the previous year [7][24] - Abbott reaffirms its full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales [17] Financial Performance - Total reported sales for the third quarter were $11.369 billion, with U.S. sales at $4.299 billion and international sales at $7.070 billion [4] - The organic sales growth was 5.5%, or 7.5% when excluding COVID-19 testing-related sales [7] - Year-to-date sales for the first nine months of 2025 reached $32.869 billion, a 6.1% increase from $30.976 billion in the same period of 2024 [24] Segment Performance - Nutrition segment sales for Q3 2025 were $2.153 billion, with U.S. sales declining by 6.5% and international sales increasing by 13.3% [6][9] - Diagnostics segment reported sales decreased by 6.6% to $2.253 billion, with a notable decline in COVID-19 testing sales from $265 million in Q3 2024 to $69 million in Q3 2025 [10][11] - Medical Devices segment sales increased by 14.8% to $5.448 billion, driven by strong growth in Diabetes Care and other areas [15][16] Guidance and Future Outlook - Abbott has narrowed its full-year 2025 adjusted diluted EPS guidance range to $5.12 to $5.18, indicating double-digit growth at the midpoint [7][17] - The company received regulatory approvals for new products, including TriClip and an expanded indication for the Navitor TAVI system, which are expected to contribute to future growth [7] Dividend Information - Abbott declared a quarterly dividend of $0.59 per share, marking the 407th consecutive quarterly dividend, with a history of increasing dividends for 53 consecutive years [19]